Cargando…
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883562/ https://www.ncbi.nlm.nih.gov/pubmed/34320786 http://dx.doi.org/10.3324/haematol.2021.278855 |
| _version_ | 1784659965783310336 |
|---|---|
| author | Wang, Chen McGraw, Kathy L. McLemore, Amy F. Komrokji, Rami Basiorka, Ashley A. Al Ali, Najla Lancet, Jeffrey E. Padron, Eric Kosmider, Olivier Fontenay, Michaela Fenaux, Pierre List, Alan F. Sallman, David A. |
| author_facet | Wang, Chen McGraw, Kathy L. McLemore, Amy F. Komrokji, Rami Basiorka, Ashley A. Al Ali, Najla Lancet, Jeffrey E. Padron, Eric Kosmider, Olivier Fontenay, Michaela Fenaux, Pierre List, Alan F. Sallman, David A. |
| author_sort | Wang, Chen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8883562 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88835622022-03-18 Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin Wang, Chen McGraw, Kathy L. McLemore, Amy F. Komrokji, Rami Basiorka, Ashley A. Al Ali, Najla Lancet, Jeffrey E. Padron, Eric Kosmider, Olivier Fontenay, Michaela Fenaux, Pierre List, Alan F. Sallman, David A. Haematologica Letters to the Editor Fondazione Ferrata Storti 2021-08-05 /pmc/articles/PMC8883562/ /pubmed/34320786 http://dx.doi.org/10.3324/haematol.2021.278855 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Wang, Chen McGraw, Kathy L. McLemore, Amy F. Komrokji, Rami Basiorka, Ashley A. Al Ali, Najla Lancet, Jeffrey E. Padron, Eric Kosmider, Olivier Fontenay, Michaela Fenaux, Pierre List, Alan F. Sallman, David A. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin |
| title | Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin |
| title_full | Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin |
| title_fullStr | Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin |
| title_full_unstemmed | Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin |
| title_short | Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin |
| title_sort | dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883562/ https://www.ncbi.nlm.nih.gov/pubmed/34320786 http://dx.doi.org/10.3324/haematol.2021.278855 |
| work_keys_str_mv | AT wangchen dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT mcgrawkathyl dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT mclemoreamyf dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT komrokjirami dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT basiorkaashleya dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT alalinajla dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT lancetjeffreye dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT padroneric dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT kosmiderolivier dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT fontenaymichaela dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT fenauxpierre dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT listalanf dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin AT sallmandavida dualpyroptoticbiomarkerspredicterythroidresponseinlowerrisknondel5qmyelodysplasticsyndromestreatedwithlenalidomideandrecombinanterythropoietin |